Scleroderma, Systemic: Clinical Trials

763 trials for Scleroderma, Systemic, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

321 completed, 141 recruiting, 110 unknown, 61 not yet recruiting. 201 Phase 2, 180 Not applicable, 126 Phase 1, 73 Phase 3, 32 Early Phase 1.

By phase and status

PhaseTrialsStatus
Phase 2201Completed 87, Recruiting 39, Terminated 26, Unknown 17, Not yet recruiting 16, Active not recruiting 7, Withdrawn 6, Suspended 2, Enrolling by invitation 1
Not applicable180Completed 93, Unknown 31, Recruiting 25, Not yet recruiting 10, Terminated 10, Active not recruiting 7, Withdrawn 3, Enrolling by invitation 1
Phase 1126Recruiting 40, Completed 34, Not yet recruiting 16, Terminated 14, Unknown 8, Withdrawn 6, Active not recruiting 4, Enrolling by invitation 3, Suspended 1
Phase 373Completed 41, Unknown 9, Recruiting 8, Terminated 7, Active not recruiting 4, Not yet recruiting 3, Withdrawn 1
Early Phase 132Not yet recruiting 9, Recruiting 9, Completed 5, Unknown 3, Active not recruiting 2, Suspended 2, Withdrawn 2
Phase 424Completed 10, Unknown 5, Active not recruiting 2, Recruiting 2, Terminated 2, Withdrawn 2, Enrolling by invitation 1

Follow Scleroderma, Systemic: new trials by email Literature Review of Scleroderma, Systemic trials Research Report on Scleroderma, Systemic

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Systemic Sclerosis (SSc) Refractory to Standard Therapy
C-CAR168 - Systemic Sclerosis (SSc), Systemic Sclerosis
Phase 1Not yet recruitingAbelZeta Inc.122027-03-012026-10-13
A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis
BMS-986353, Fludarabine, Cyclophosphamide - Systemic Sclerosis
Phase 3Not yet recruitingJuno Therapeutics, Inc., a Bristol-Myers Squibb Company922027-02-032026-09-18
Efficacy and Safety Study of L608 in Patients With Systemic Sclerosis-associated Digital Ulcers
L608, Placebo - Systemic Sclerosis
Phase 2Not yet recruitingPharmosa Biopharm Inc.402027-02-012026-11-09
An Open-label Phase I/II Safety and Feasibility Basket Study of UKT-CART19.1
CAR-T cells targeting CD19 - Pemphigus Vulgaris (PV), ANCA Associated Vasculitis (AAV)
Phase 1 / Phase 2Not yet recruitingUniversity Hospital Tuebingen362027-01-012026-11-12
Safety and Preliminary Efficacy of HN2302 in Patients With Autoimmune Diseases
HN2302 Injection - Autoimmune Disease, Systemic Lupus Erythematosus
Phase 1Not yet recruitingShenzhen MagicRNA Biotechnology Co., Ltd122026-12-312026-08-12
A Study to Evaluate the Safety and Efficacy (How Well the Study Treatment Works) of ABBV-2294 in Adult Participants With Systemic Sclerosis That Are Currently Receiving Local Standard of Care Treatment, and to Determine the Best Dose of ABBV-2294 to be Evaluated Further.
ABBV-722, Upadacitinib, Placebo for ABBV-722 - Systemic Sclerosis
Phase 2 / Phase 3Not yet recruitingAbbVie5802026-12-112026-11-18
Mycophenolate After Stem Cell Transplant for Systemic Sclerosis
Mycophenolate Mofetil 1000 mg twice daily - Systemic Sclerosis (SSc)
Phase 2Not yet recruitingOttawa Hospital Research Institute62026-12-012026-10-19
Study Investigating the Safety of Anti-CD19 CAR-T Cells Therapy Produced at Gustave Roussy for Adults With Severe and Refractory Systemic Autoimmune Rheumatic Diseases
anti-CD19 CAR-T cells - Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE)
Phase 1Not yet recruitingGustave Roussy, Cancer Campus, Grand Paris62026-12-012026-09-02
Investigation of Type I Interferon Excess in Patients With Systemic Autoimmune Diseases and Genetic Type I Interferonopathies
biological samples - Systememic Lupus Erythematosus, Systemic Sclerosis (SSc)
Not applicableNot yet recruitingHospices Civils de Lyon1202026-12-012026-09-24
Hyaluronidase Injections for Sclerodactyly in Patients With Scleroderma
hyaluronidase - Scleroderma, Sclerodactyly
Phase 2Not yet recruitingStanford University102026-12-012026-11-06
A Phase 1 Study of QLS2416 Injection in Participants With Autoimmune Diseases
QLS2416 Injection - Systemic Lupus Erythematosus, Rheumatoid Arthritis (RA)
Phase 1Not yet recruitingShanghai Qilu Pharmaceutical Research and Development Center LTD762026-12-012026-10-30
Inflammatory Disease Biobank for Immunophenotyping and Cardiovascular Research
Pericarditis, Tako-TSUBO Cardiomyopathy
Not yet recruitingAssistance Publique - Hôpitaux de Paris3002026-12-012026-11-13
Dual-targeting of B & T Cell Pathways Evaluation Trial
DFI205 bispecific antibody - Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE)
Phase 1 / Phase 2RecruitingDiabetes Free, Inc.722026-12-012026-11-18
A Study to Learn About a Medicine Called PF-08154225 in Participants With Autoimmune Diseases
PF-08154225 - Systemic Lupus Erythematosus, Rheumatoid Arthritis
Phase 1 / Phase 2Not yet recruitingPfizer542026-11-192026-10-01
Safety and Efficacy of Universal CAR-T Cells (UWD-CD19) Combined With Immunosuppressants in the Treatment of Refractory Autoimmune Diseases
anti-CD19 CAR-T cells - Systemic Lupus Erthematosus, Systemic Sclerosis (SSc)
Phase 1 / Phase 2Not yet recruitingPeking University Third Hospital92026-11-012026-09-23
Catestatin as a Novel Biomarker for Cardiovascular and Microvascular Involvement in Systemic Sclerosis
Systemic Sclerosis
Not yet recruitingAssiut University702026-11-012025-10-07
Hyaluronidase for Sclerodactyly in Systemic Sclerosis Trial
Hyaluronidase (Hylenex) - Systemic Sclerosis, Sclerodactyly
Early Phase 1Not yet recruitingMedical University of South Carolina102026-11-012026-10-16
Hyperpolarized Xenon MRI in Adults With Pulmonary Hypertension in Interstitial Lung Disease and Systemic Sclerosis
Hyperpolarized 129 Xenon Gas - Interstitial Lung Disease, Pulmonary Hypertension
Phase 2Not yet recruitingBastiaan Driehuys512026-11-012026-09-15
Obinutuzumab in Systemic Sclerosis
Obinutuzumab, Placebo - Systemic Sclerosis in Adults
Phase 2Not yet recruitingAssistance Publique - Hôpitaux de Paris1202026-11-012026-09-25
Using AI-Assisted Cameras to Track Hand Exercises in Scleroderma Patients
AI-powered, camera-based, exercise-focused telerehabilitation, Physiotherapist-supervised, exercise-focused rehabilitation - Systemic Scleroderma
Not applicableNot yet recruitingIstanbul University - Cerrahpasa402026-11-012026-10-14

Showing 20 of 763. Sign in to see all of them.

Narrower conditions

Scleroderma, Diffuse (310)  ·  Lupus Erythematosus, Systemic (117)  ·  Arthritis, Rheumatoid (75)  ·  Myositis (74)  ·  Autoimmune Diseases (67)  ·  Sjogren's Syndrome (59)  ·  Lung Diseases, Interstitial (51)  ·  Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (43)  ·  Raynaud Disease (43)  ·  Dermatomyositis (35)  ·  Hypertension, Pulmonary (32)  ·  Connective Tissue Diseases (31)  ·  digital ulcers (26)  ·  Antiphospholipid Syndrome (21)

Broader conditions

Skin and Connective Tissue Diseases (763)  ·  Skin Diseases (754)  ·  Connective Tissue Diseases (732)  ·  Immune System Diseases (190)  ·  Musculoskeletal Diseases (159)  ·  Cardiovascular Diseases (147)  ·  Vascular Diseases (142)  ·  Autoimmune Diseases (123)  ·  Joint Diseases (122)  ·  Nervous System Diseases (120)  ·  Respiratory Tract Diseases (117)  ·  Arthritis (109)  ·  Lung Diseases (108)  ·  Neuromuscular Diseases (107)

Interventions

Cyclophosphamide (32)  ·  Blood Specimen Collection (21)  ·  Mycophenolic Acid (19)  ·  fludarabine (18)  ·  Bosentan (12)  ·  Rituximab (12)  ·  Imatinib Mesylate (8)  ·  tocilizumab (7)  ·  Methotrexate (6)  ·  Nitroglycerin (6)  ·  Sildenafil Citrate (6)  ·  Surveys and Questionnaires (6)  ·  fludarabine phosphate (6)  ·  treprostinil (6)  ·  Hematologic Tests (5)

Sponsors

Assistance Publique - Hôpitaux de Paris (25)  ·  University of Michigan (20)  ·  University Hospital, Lille (14)  ·  Assiut University (13)  ·  Actelion (11)  ·  University Hospital, Strasbourg, France (11)  ·  Johns Hopkins University (10)  ·  Lady Davis Institute (9)  ·  Duke University (8)  ·  Assistance Publique Hopitaux De Marseille (7)  ·  Istanbul University (7)  ·  University Hospital, Bordeaux (7)  ·  Hacettepe University (6)  ·  Khon Kaen University (6)  ·  MediQuest Therapeutics (6)

Countries

United States (245)  ·  France (150)  ·  China (87)  ·  United Kingdom (73)  ·  Germany (63)  ·  Italy (60)  ·  Canada (56)  ·  Spain (49)  ·  Turkey (Türkiye) (41)  ·  Poland (36)  ·  Switzerland (32)  ·  Belgium (30)  ·  Australia (28)  ·  Netherlands (28)  ·  Israel (24)

Top investigators

David Launay, MD,PhD (7)  ·  Robert Spiera, MD (5)  ·  Keith Sullivan, MD (4)  ·  Luc Mouthon, MD, PhD (4)  ·  Richard Burt, MD (4)  ·  Robert Lafyatis, MD (4)  ·  Anna-Maria Hoffmann-Vold, MD, PhD (3)  ·  Dinesh Khanna, MD (3)

Results publications

PMID 37929840, PMID 41217519, PMID 16790698, PMID 17717203, PMID 17901414, PMID 18641099, PMID 19892673, PMID 24092682, PMID 25452309, PMID 27163986, PMID 27941129, PMID 28298564, PMID 28544580, PMID 29099620, PMID 29381834, PMID 30651141, PMID 31219594, PMID 33294861, PMID 33481429, PMID 33765691, PMID 35904231, PMID 38501358, PMID 41316297, PMID 11934971, PMID 12355489, PMID 12524257, PMID 15692967, PMID 15942915, PMID 16055882, PMID 16142864, PMID 16738459, PMID 16840399, PMID 16960939, PMID 16987829, PMID 17234649, PMID 17469162, PMID 17471524, PMID 17485423, PMID 17974598, PMID 18092268, PMID 18512816, PMID 18634152, PMID 18843713, PMID 19103636, PMID 19158116, PMID 19180499, PMID 19207142, PMID 19420368, PMID 19642060, PMID 19644906

NIH funding

2023 (9), 2019 (6), 2025 (6), 2018 (5), 2015 (4), 2014 (3), 2016 (2), P30CA015704 (2), 1UM1AI110557 (1), 2005 (1), 2008 (1), 2017 (1), K12HD055884 (1), K23AR002187 (1), N01AR002251 (1)